Methylation status, mRNA and protein expression of the SMAD4 gene in patients with non-melanocytic skin cancers.
Basal cell carcinoma
DNA methylation
SMAD4 protein
Squamous cell carcinoma
mRNA
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
29
03
2023
accepted:
29
06
2023
medline:
29
8
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
ppublish
Résumé
SMAD4 is a potent tumor suppressor. SMAD4 loss increases genomic instability and plays a critical role in the DNA damage response that leads to skin cancer development. We aimed to investigate SMAD4 methylation effects on mRNA and protein expression of SMAD4 in cancer and healthy tissues from patients with basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and basosquamous skin cancer (BSC). The study included 17 BCC, 24 cSCC and nine BSC patients. DNA and RNA were isolated from cancerous and healthy tissues following punch biopsy. Methylation-specific polymerase chain reaction (PCR) and real-time quantitative PCR methods were used to examine SMAD4 promoter methylation and SMAD4 mRNA levels, respectively. The percentage and intensity of staining of the SMAD4 protein were determined by immunohistochemistry. The percentage of SMAD4 methylation was increased in the patients with BCC (p = 0.007), cSCC (p = 0.004), and BSC (p = 0.018) compared to the healthy tissue. SMAD4 mRNA expression was decreased in the patients with BCC (p˂0.001), cSCC (p˂0.001), and BSC (p = 0.008). The staining characteristic of SMAD4 protein was negative in the cancer tissues of the patients with cSCC (p = 0.00). Lower SMAD4 mRNA levels were observed in the poorly differentiated cSCC patients (p = 0.001). The staining characteristics of the SMAD4 protein were related to age and chronic sun exposure. Hypermethylation of SMAD4 and reduced SMAD4 mRNA expression were found to play a role in the pathogenesis of BCC, cSCC, and BSC. A decrease in SMAD4 protein expression level was observed only in cSCC patients. This suggests that epigenetic alterations to the SMAD4 gene are associated with cSCC. The name of the trial register: SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity. The registration number: NCT04759261 ( https://clinicaltrials.gov/ct2/results?term=NCT04759261 ).
Sections du résumé
BACKGROUND
BACKGROUND
SMAD4 is a potent tumor suppressor. SMAD4 loss increases genomic instability and plays a critical role in the DNA damage response that leads to skin cancer development. We aimed to investigate SMAD4 methylation effects on mRNA and protein expression of SMAD4 in cancer and healthy tissues from patients with basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and basosquamous skin cancer (BSC).
METHODS AND RESULTS
RESULTS
The study included 17 BCC, 24 cSCC and nine BSC patients. DNA and RNA were isolated from cancerous and healthy tissues following punch biopsy. Methylation-specific polymerase chain reaction (PCR) and real-time quantitative PCR methods were used to examine SMAD4 promoter methylation and SMAD4 mRNA levels, respectively. The percentage and intensity of staining of the SMAD4 protein were determined by immunohistochemistry. The percentage of SMAD4 methylation was increased in the patients with BCC (p = 0.007), cSCC (p = 0.004), and BSC (p = 0.018) compared to the healthy tissue. SMAD4 mRNA expression was decreased in the patients with BCC (p˂0.001), cSCC (p˂0.001), and BSC (p = 0.008). The staining characteristic of SMAD4 protein was negative in the cancer tissues of the patients with cSCC (p = 0.00). Lower SMAD4 mRNA levels were observed in the poorly differentiated cSCC patients (p = 0.001). The staining characteristics of the SMAD4 protein were related to age and chronic sun exposure.
CONCLUSIONS
CONCLUSIONS
Hypermethylation of SMAD4 and reduced SMAD4 mRNA expression were found to play a role in the pathogenesis of BCC, cSCC, and BSC. A decrease in SMAD4 protein expression level was observed only in cSCC patients. This suggests that epigenetic alterations to the SMAD4 gene are associated with cSCC.
TRIAL REGISTRATION
BACKGROUND
The name of the trial register: SMAD4 Methylation and Expression Levels in Non-melanocytic Skin Cancers; SMAD4 Protein Positivity. The registration number: NCT04759261 ( https://clinicaltrials.gov/ct2/results?term=NCT04759261 ).
Identifiants
pubmed: 37428273
doi: 10.1007/s11033-023-08656-2
pii: 10.1007/s11033-023-08656-2
doi:
Substances chimiques
Smad4 Protein
0
RNA, Messenger
0
SMAD4 protein, human
0
Banques de données
ClinicalTrials.gov
['NCT04759261']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7295-7304Subventions
Organisme : Trakya Üniversitesi
ID : 2020/55
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Ciążyńska M, Kamińska-Winciorek G, Lange D et al (2021) The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep 11:4337. https://doi.org/10.1038/s41598-021-83502-8
doi: 10.1038/s41598-021-83502-8
pubmed: 33619293
pmcid: 7900109
Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
pubmed: 33538338
Zambrano-Román M, Padilla-Gutiérrez JR, Valle Y, Muñoz-Valle JF, Valdés-Alvarado E (2022) Non-melanoma skin cancer: a genetic update and future perspectives. Cancers 14:2371. https://doi.org/10.3390/cancers14102371
doi: 10.3390/cancers14102371
pubmed: 35625975
pmcid: 9139429
Chiang A, Tan CZ, Kuonen F et al (2019) Genetic mutations underlying phenotypic plasticity in basosquamous carcinoma. J Invest Dermatol 139:2263-2271e5. https://doi.org/10.1016/j.jid.2019.03.1163
doi: 10.1016/j.jid.2019.03.1163
pubmed: 31207229
pmcid: 6839544
Volkenstein S, Wohlschlaeger J, Liebau J et al (2010) Basosquamous carcinoma–a rare but aggressive skin malignancy. J Plast Reconstr Aesthet Surg 63:e304–306. https://doi.org/10.1016/j.bjps.2009.05.058
doi: 10.1016/j.bjps.2009.05.058
pubmed: 19647505
Tarapore E, Atwood SX (2019) Defining the genetics of basosquamous carcinoma. J Invest Dermatol 139:2258–2260. https://doi.org/10.1016/j.jid.2019.04.011
doi: 10.1016/j.jid.2019.04.011
pubmed: 31648686
Cives M, Mannavola F, Lospalluti L et al (2020) Non-melanoma skin cancers: biological and clinical features. Int J Mol Sci 21:5394. https://doi.org/10.3390/ijms21155394
doi: 10.3390/ijms21155394
pubmed: 32751327
pmcid: 7432795
Calzavara-Pinton P, Ortel B, Venturini M (2015) Non-melanoma skin cancer, sun exposure and sun protection. G Ital Dermatol Venereol 150:369–378
pubmed: 26186380
Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31–46. https://doi.org/10.1158/2159-8290.Cd-21-1059
doi: 10.1158/2159-8290.Cd-21-1059
pubmed: 35022204
Pacella G, Capell BC (2021) Epigenetic and metabolic interplay in cutaneous squamous cell carcinoma. Exp Dermatol 30:1115–1125. https://doi.org/10.1111/exd.14354
doi: 10.1111/exd.14354
pubmed: 33844325
pmcid: 8324523
Zhou C, Ye M, Ni S et al (2018) DNA methylation biomarkers for head and neck squamous cell carcinoma. Epigenetics 13:398–409. https://doi.org/10.1080/15592294.2018.1465790
doi: 10.1080/15592294.2018.1465790
pubmed: 29927694
pmcid: 6140809
Ke Y, Wang XJ (2021) TGFβ signaling in photoaging and UV-Induced skin cancer. J Invest Dermatol 141:1104–1110. https://doi.org/10.1016/j.jid.2020.11.007
doi: 10.1016/j.jid.2020.11.007
pubmed: 33358021
pmcid: 7987776
Shao Y, Zhang J, Zhang R, Wan J, Zhang W, Yu B (2012) Examination of Smad2 and Smad4 copy-number variations in skin cancers. Clin Transl Oncol 14:138–142. https://doi.org/10.1007/s12094-012-0773-7
doi: 10.1007/s12094-012-0773-7
pubmed: 22301403
Kim Y, He YY (2014) Ultraviolet radiation-induced non-melanoma skin cancer: regulation of DNA damage repair and inflammation. Genes Dis 1:188–198. https://doi.org/10.1016/j.gendis.2014.08.005
doi: 10.1016/j.gendis.2014.08.005
pubmed: 25642450
pmcid: 4307792
Zhao M, Mishra L, Deng CX (2018) The role of TGF-β/SMAD4 signaling in cancer. Int J Biol Sci 14:111–123. https://doi.org/10.7150/ijbs.23230
doi: 10.7150/ijbs.23230
pubmed: 29483830
pmcid: 5821033
Yang L, Mao C, Teng Y et al (2005) Targeted disruption of Smad4 in mouse epidermis results in failure of hair follicle cycling and formation of skin tumors. Cancer Res 65:8671–8678. https://doi.org/10.1158/0008-5472.Can-05-0800
doi: 10.1158/0008-5472.Can-05-0800
pubmed: 16204035
Cai H, Sobue T, Kitamura T et al (2020) Epidemiology of nonmelanoma skin cancer in Japan: occupational type, lifestyle, and family history of cancer. Cancer Sci 111:4257–4265. https://doi.org/10.1111/cas.14619
doi: 10.1111/cas.14619
pubmed: 33448530
pmcid: 7648044
Khalesi M, Whiteman DC, Rosendahl C et al (2015) Basal cell carcinomas on sun-protected vs. sun-exposed body sites: a comparison of phenotypic and environmental risk factors. Photodermatol Photoimmunol Photomed 31:202–211. https://doi.org/10.1111/phpp.12170
doi: 10.1111/phpp.12170
pubmed: 25787710
Reiter O, Mimouni I, Dusza S, Halpern AC, Leshem YA, Marghoob AA (2021) Dermoscopic features of basal cell carcinoma and its subtypes: a systematic review. J Am Acad Dermatol 85:653–664. https://doi.org/10.1016/j.jaad.2019.11.008
doi: 10.1016/j.jaad.2019.11.008
pubmed: 31706938
Sgouros D, Theofili M, Damaskou V et al (2021) Dermoscopy as a tool in differentiating cutaneous squamous cell carcinoma from its variants. Dermatol Pract Concept 11:e2021050. https://doi.org/10.5826/dpc.1102a50
doi: 10.5826/dpc.1102a50
pubmed: 33954021
pmcid: 8060018
Gambichler T, Skrygan M, Kaczmarczyk JM et al (2007) Increased expression of TGF-beta/Smad proteins in basal cell carcinoma. Eur J Med Res 12:509–514
pubmed: 18024258
Ozkan U, Ozcelik F, Yildiz M, Budak M (2019) Lipoprotein(a) gene polymorphism increases a risk factor for aortic valve calcification. J Cardiovasc Dev Dis 6:31. https://doi.org/10.3390/jcdd6030031
doi: 10.3390/jcdd6030031
pubmed: 31455005
pmcid: 6787733
Gao T, Nie Y, Guo J (2012) Hypermethylation of the gene LARP2 for noninvasive prenatal diagnosis of β-thalassemia based on DNA methylation profile. Mol Biol Rep 39:6591–6598. https://doi.org/10.1007/s11033-012-1489-z
doi: 10.1007/s11033-012-1489-z
pubmed: 22327645
Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Shan B (2012) Concordant repression and aberrant methylation of transforming growth factor-beta signaling pathway genes occurs early in gastric cardia adenocarcinoma. Mol Biol Rep 39:9453–9462. https://doi.org/10.1007/s11033-012-1810-x
doi: 10.1007/s11033-012-1810-x
pubmed: 22722999
Li LC, Dahiya R (2002) MethPrimer: designing primers for methylation PCRs. Bioinformatics 18:1427–1431. https://doi.org/10.1093/bioinformatics/18.11.1427
doi: 10.1093/bioinformatics/18.11.1427
pubmed: 12424112
Rao X, Huang X, Zhou Z, Lin X (2013) An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath 3:71–85
pubmed: 25558171
pmcid: 4280562
Lin Z, Zhang L, Zhou J, Zheng J (2019) Silencing Smad4 attenuates sensitivity of colorectal cancer cells to cetuximab by promoting epithelialmesenchymal transition. Mol Med Rep 20:3735–3745. https://doi.org/10.3892/mmr.2019.10597
doi: 10.3892/mmr.2019.10597
pubmed: 31485652
pmcid: 6755154
Xavier-Junior JCC, Ocanha-Xavier JP (2019) WHO,(2018) Classification of Skin Tumors. Am J Dermatopathol 41:699–700. https://doi.org/10.1097/dad.0000000000001446
doi: 10.1097/dad.0000000000001446
Woo WA, Suarez MFB, Keohane SG (2021) Summary of the updated 2020 guidelines for cutaneous squamous cell carcinoma. Clin Exp Dermatol 46:1174–1177. https://doi.org/10.1111/ced.14587
doi: 10.1111/ced.14587
pubmed: 33729596
He SM, Zhao ZW, Wang Y et al (2011) Reduced expression of SMAD4 in gliomas correlates with progression and survival of patients. J Exp Clin Cancer Res 30:70. https://doi.org/10.1186/1756-9966-30-70
doi: 10.1186/1756-9966-30-70
pubmed: 21791112
pmcid: 3160899
Hernandez AL, Young CD, Wang JH, Wang XJ (2019) Lessons learned from SMAD4 loss in squamous cell carcinomas. Mol Carcinog 58:1648–1655. https://doi.org/10.1002/mc.23049
doi: 10.1002/mc.23049
pubmed: 31140647
pmcid: 6820000
Bellizzi AM (2020) An algorithmic immunohistochemical approach to define tumor type and assign site of origin. Adv Anat Pathol 27:114–163. https://doi.org/10.1097/pap.0000000000000256
doi: 10.1097/pap.0000000000000256
pubmed: 32205473
pmcid: 7700753
Hoot KE, Lighthall J, Han G et al (2008) Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. J Clin Invest 118:2722–2732. https://doi.org/10.1172/jci33713
doi: 10.1172/jci33713
pubmed: 18618014
pmcid: 2447925
Mitra D, Fernandez P, Bian L et al (2013) Smad4 loss in mouse keratinocytes leads to increased susceptibility to UV carcinogenesis with reduced Ercc1-mediated DNA repair. J Invest Dermatol 133:2609–2616. https://doi.org/10.1038/jid.2013.213
doi: 10.1038/jid.2013.213
pubmed: 23648546
pmcid: 3783584
Hatziapostolou M, Iliopoulos D (2011) Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68:1681–1702. https://doi.org/10.1007/s00018-010-0624-z
doi: 10.1007/s00018-010-0624-z
pubmed: 21249513
Swellam M, Saad EA, Sabry S, Denewer A, Abdel Malak C, Abouzid A (2021) Alterations of PTEN and SMAD4 methylation in diagnosis of breast cancer: implications of methyl II PCR assay. J Genet Eng Biotechnol 19:54. https://doi.org/10.1186/s43141-021-00154-x
doi: 10.1186/s43141-021-00154-x
pubmed: 33825073
pmcid: 8024427
Yan W, Wistuba II, Emmert-Buck MR, Erickson HS (2011) Squamous cell carcinoma—similarities and differences among anatomical sites. Am J Cancer Res 1:275–300
pubmed: 21938273
Wu F, Weigel KJ, Zhou H, Wang XJ (2018) Paradoxical roles of TGF-β signaling in suppressing and promoting squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai) 50:98–105. https://doi.org/10.1093/abbs/gmx127
doi: 10.1093/abbs/gmx127
pubmed: 29206939
Bornstein S, White R, Malkoski S et al (2009) Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation. J Clin Invest 119:3408–3419. https://doi.org/10.1172/jci38854
doi: 10.1172/jci38854
pubmed: 19841536
pmcid: 2769185
Franzen A, Bootz F, Dietrich D (2020) Prognostic and predictive methylation biomarkers in HNSCC: Epigenomic diagnostics for head and neck squamous cell carcinoma (HNSCC). HNO 68:911–915. https://doi.org/10.1007/s00106-020-00902-4
doi: 10.1007/s00106-020-00902-4
pubmed: 32613323
Nikolouzakis TK, Falzone L, Lasithiotakis K et al (2020) Current and future trends in molecular biomarkers for diagnostic, prognostic, and predictive purposes in non-melanoma skin cancer. J Clin Med 9:2868. https://doi.org/10.3390/jcm9092868
doi: 10.3390/jcm9092868
pubmed: 32899768
pmcid: 7564050
Lin LH, Chang KW, Cheng HW, Liu CJ (2019) SMAD4 somatic mutations in head and neck carcinoma are associated with tumor progression. Front Oncol 9:1379. https://doi.org/10.3389/fonc.2019.01379
doi: 10.3389/fonc.2019.01379
pubmed: 31867281
pmcid: 6909744
Hervás-Marín D, Higgins F, Sanmartín O et al (2019) Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma. PLoS ONE 14:e0223341. https://doi.org/10.1371/journal.pone.0223341
doi: 10.1371/journal.pone.0223341
pubmed: 31860637
pmcid: 6924689
Heitzer E, Bambach I, Dandachi N, Horn M, Wolf P (2010) PTCH promoter methylation at low level in sporadic basal cell carcinoma analysed by three different approaches. Exp Dermatol 19:926–928. https://doi.org/10.1111/j.1600-0625.2010.01120.x
doi: 10.1111/j.1600-0625.2010.01120.x
pubmed: 20849535
Brinkhuizen T, van den Hurk K, Winnepenninckx VJ et al (2012) Epigenetic changes in basal cell carcinoma affect SHH and WNT signaling components. PLoS ONE 7:e51710. https://doi.org/10.1371/journal.pone.0051710
doi: 10.1371/journal.pone.0051710
pubmed: 23284750
pmcid: 3524166
Qiao W, Li AG, Owens P, Xu X, Wang XJ, Deng CX (2006) Hair follicle defects and squamous cell carcinoma formation in Smad4 conditional knockout mouse skin. Oncogene 25:207–217. https://doi.org/10.1038/sj.onc.1209029
doi: 10.1038/sj.onc.1209029
pubmed: 16170355
Lange D, Persson U, Wollina U et al (1999) Expression of TGF-beta related smad proteins in human epithelial skin tumors. Int J Oncol 14:1049–1056. https://doi.org/10.3892/ijo.14.6.1049
doi: 10.3892/ijo.14.6.1049
pubmed: 10339656
Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M et al (2014) Discordant expression of desmoglein 2 and 3 at the mRNA and protein levels in nodular and superficial basal cell carcinoma revealed by immunohistochemistry and fluorescent in situ hybridization. Clin Exp Dermatol 39:628–635. https://doi.org/10.1111/ced.12355
doi: 10.1111/ced.12355
pubmed: 24934917
Li JJ, Biggin MD (2015) Gene expression. Statistics requantitates the central dogma. Science 347:1066–1067. https://doi.org/10.1126/science.aaa8332
doi: 10.1126/science.aaa8332
pubmed: 25745146
Fortelny N, Overall CM, Pavlidis P, Freue GVC (2017) Can we predict protein from mRNA levels? Nature 547:E19–E20. https://doi.org/10.1038/nature22293
doi: 10.1038/nature22293
pubmed: 28748932